Neuroscience Strategic Roundup: Emerging Therapies and Competitive Shifts | Sep 29–Nov 3, 2026
Neuroscience trends signal a competitive shift toward stronger clinical…
Georgiamune and Menarini Sign $1.1B GIM-621 Licensing Deal | Lucid Diligence Brief
This Lucid Diligence Brief explores Georgiamune and Menarini’s $1.1 billion…
Neuroscience Strategic Roundup: From Efficacy to Differentiation | Aug 25–Sept 29, 2026
Current neuroscience trends point to a broader competitive shift, as treatment…
Neuroscience Strategic Roundup | June17–July 21, 2026
Strategic Developments and Competitive Shifts in Neuroscience Coverage Period:…
Excalipoint Therapeutics and DP Technology Partnership | Lucid Diligence Brief
Excalipoint Therapeutics and DP Technology have partnered to develop an agentic…
Lonza Antharis Dual-Payload ADC License | Lucid Diligence Brief
Lonza and Antharis license dual-payload ADC technology for gastrointestinal…
Public Health Today—June 5, 2026
This weekly update in Public Health highlights major developments across…
Lucid Diligence Brief: Bayer to Acquire Perfuse Therapeutics for Up to $2.45B
Lucid Diligence Brief: Bayer to Acquire Perfuse Therapeutics for Up to $2.45B…
Lucid Diligence Brief: Merck × Google Cloud agentic AI partnership
Lucid Diligence Brief: Merck × Google Cloud agentic AI partnership Professional…
Lucid Diligence Brief: Beeline Medicines debuts with $300M Series A
Lucid Diligence Brief: Beeline Medicines debuts with $300M Series A…
Lucid Diligence Brief: InSilico Medicine and Lilly global partnership
Lucid Diligence Brief: InSilico Medicine and Lilly global partnership…
Lucid Diligence Brief: Quotient and MSD ink a $2.2 billion IBD drug discovery deal
Lucid Diligence Brief: Quotient and MSD ink a $2.2 billion IBD drug discovery…